Zuellig Pharma Sustainability Profile
Zuellig Pharma, a leading healthcare services provider, is headquartered in Singapore and operates extensively across Asia. Founded in 1922, the company has established itself as a key player in the pharmaceutical distribution and healthcare solutions industry, serving markets in over 13 countries, including China, Malaysia, and the Philippines. Specialising in supply chain management, logistics, and market access services, Zuellig Pharma is renowned for its innovative approach to healthcare delivery. The company’s unique offerings include advanced temperature-controlled logistics and digital health solutions, which enhance patient access to essential medicines. With a strong market position, Zuellig Pharma has achieved numerous milestones, including partnerships with major pharmaceutical companies and recognition for its commitment to improving healthcare outcomes in the region. Its dedication to quality and efficiency continues to set it apart in the competitive landscape of healthcare services.
DitchCarbon Score
How does Zuellig Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zuellig Pharma's score of 68 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zuellig Pharma's reported carbon emissions
In 2024, Zuellig Pharma reported total carbon emissions of approximately 232,316,000 kg CO2e, a decrease from about 296,469,000 kg CO2e in 2023. The emissions breakdown for 2024 includes 14,728,000 kg CO2e from Scope 1, 22,222,000 kg CO2e from Scope 2 (market-based), and a significant 165,366,000 kg CO2e from Scope 3 emissions. This indicates a notable shift in their emissions profile, particularly in Scope 3, which encompasses indirect emissions from the supply chain and product use. Zuellig Pharma has set ambitious climate commitments, aiming for a 42% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2030, using 2021 as the base year. Additionally, they target a 25% reduction in absolute Scope 3 emissions related to fuel and energy activities, upstream transportation, and waste generated in operations within the same timeframe. The emissions data for Zuellig Pharma is cascaded from its parent company, Zuellig Pharma Holdings, reflecting a corporate commitment to sustainability across its operations. This structured approach to emissions reporting and reduction aligns with industry standards and demonstrates Zuellig Pharma's proactive stance on climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,336,336 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 76,839 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Zuellig Pharma's Industry?
How Carbon Intensive is Zuellig Pharma's Location?
Zuellig Pharma's Scope 3 Categories Breakdown
Zuellig Pharma's Scope 3 emissions, which decreased by 36% last year and increased significantly since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 48% of Scope 3 emissions.
Top Scope 3 Categories
Zuellig Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zuellig Pharma has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
